Fundraising FoxARCH Venture Partners — 2023 Investments
14 investments dated 2023 · listed companies and verified rows first · show all
Neumora is a clinical research company developing investigational medications, with a focus on conducting clinical trials to obtain regulatory approval and make treatments available to patients.
BiotechDeep TechDigital HealthMedical DevicesWatertown, US
Paul L. Berns(Chairman and Chief Executive Officer)Joshua Pinto(Executive Officer)Tamara Tompkins(Executive Officer)inKari Stefansson(Director)Maykin Ho(Director)Alaa Halawa(Director)
Board seatRobert NelsenKristina Burow· per SEC Form D
Co-investorsCatalio Capital Management, LPF-Prime CapitalK2 HealthVenturesMercury FundPremier PartnersSoftBank Vision Fund+12 more
Rapport is a biopharmaceutical company developing novel therapeutics.
BiotechHealthtechMedical Devices
Abe Ceesay(President)Cheryl GaultinDr. SevignyAbraham N. Ceesay(President and Chief Executive Officer and Director)Steven Paul David Bredt(Founder)
Co-investorsSofinnova VenturesCapital GroupJohnson & Johnson Innovation – JJDCThird Rock Ventures
Aera Therapeutics develops genetic medicines using next-generation delivery technologies and precision payloads optimized for specific diseases.
AI & Machine LearningBiotechDeep TechMedical DevicesCambridge, US
Feng Zhang, Ph.D.(Scientific Founder & Board Observer)Akin Akinc, Ph.D.(Chief Executive Officer & Board Director)Akin Akinc(Founder)Feng Zhang(Founder)Feng Zhang Akin Akinc(Founder)John Maraganore(Founder)
Co-investorsLux CapitalF-Prime CapitalGV (Google Ventures)JDRF T1D FundAltitude Ventures Management, LlcNewpath Partners
Magnet Biomedicine develops TrueGlue™, a molecular glue discovery platform for designing small molecule therapeutics that induce novel protein-protein interactions to treat cancer and immune disorders.
AI & Machine LearningBiotechMedical DevicesBoston, US
Benjamin F. Cravatt, PhD(Founder & Advisor)David A. Spiegel, MD, PhD(Founder & Advisor)Michael Rosbash, PhD(Founder & Advisor)Richa Saxena, PhD(Founder & Advisor)Stuart Schreiber, PhD(Founder & Advisor)Brian Safina(President & Chief Executive Officer)in
Co-investorsNewpath PartnersTaiho Ventures, LLC
Bethesda-based provider of in-home and virtual primary, behavioral and social care for low-income patients with complex needs.
HealthtechBethesda, US
Rahul Rajkumar(Founder)in
BoardBryan Roberts(Director)Robert Kocher(Director)Stephanie Lovell(Director)Vivian Riefberg(Director)
Co-investorsIVP (Institutional Venture Partners)VenrockVenrock Associates
Akamis Bio develops oncolytic immunotherapies for colorectal cancer treatment, aiming to offer alternatives to surgery that preserve patient function and quality of life.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsSR One Capital ManagementIP GroupLundbeckfonden VenturesWestlake Village BioPartners
Curie.Bio is a biotech venture firm pairing seed capital with in-house drug discovery support for therapeutics founders.
Zach Weinberg(Founder)inAlexis Borisy(Founder)Christoph Lengauer(Founder)
Co-investorsAlleyCorpBoxGroupDNA CapitalF-Prime CapitalGV (Google Ventures)Lightstone Ventures+5 more
Gate Bioscience develops small molecule therapeutics called Molecular Gates for disease treatment.
BiotechDeep TechMedical Devices
Jordi Mata-Fink(Chief Executive Officer, Co-Founder)inRaman Talwar(Chief Technology Officer, Co-Founder)inPat Sharp(Scientific Founder)in
Co-investorsForbionVersant VenturesAndreessen HorowitzFelicis VenturesGV (Google Ventures)
Mozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments.
BiotechMedical Devices
Mark Davis(Scientific Co-Founder)K. Christopher Garcia(Scientific Co-Founder)Calvin Kuo(Scientific Co-Founder)Katie Fanning(President & Chief Executive Officer)in
Co-investorsJDRF T1D FundMRL Ventures FundOno Venture Investment, Inc.Pfizer Venture InvestmentsSofinnova PartnersAbbVie+6 more
A pharmaceutical company developing therapeutics across oncology, hematology, neuroscience, immunology, and cardiovascular disease with a pipeline of 50 compounds targeting 40+ disease areas.
BiotechHealthtechMedical Devices
Co-investorsAndreessen HorowitziGlobe PartnersAgent CapitalAlexandriaCasdin CapitalHeritage Medical Systems+5 more
Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders.
AI & Machine LearningBiotechWatertown, US
Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)inRobert Gagnon(Executive Officer)Heather Wasserman(Executive Officer)inMatthew Patterson(Director)inScott Biller(Director)in
Co-investorsAtlas VentureForesite CapitalThe Column GroupAlexandriaDecheng Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Encentrio Therapeutics, Inc.Tome BiosciencesUltraDx Bio
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.